Episode
Fibrosis, IPF and the search for better therapies
- Podcast
- BioSpace
- Published
- May 7, 2026
- Duration seconds
- 1080
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/biospace-6696251/episodes/fibrosis-ipf-and-the-search-for-better-therapies/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/biospace-6696251/fibrosis-ipf-and-the-search-for-better-therapies.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
In this episode of Denatured, you'll be hearing from Georg Vo Beiske, CEO of Tribune Therapeutics and Jonas Hallén, co-founder & Chief Medical Officer of Calluna Pharma. We dive into IPF and fibrosis challenges, unpacking treatment hurdles, emerging targets, unmet needs and expansion paths beyond the lung. Host Jennifer C. Smith-Parker , Director of Insights, BioSpace Guests Georg Vo Beiske , CEO, Tribune Therapeutics Jonas Hallén , Co-Founder & CMO, Calluna Pharma Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.